Format

Send to

Choose Destination
Cancer Cell. 2015 Jun 8;27(6):751-3. doi: 10.1016/j.ccell.2015.05.012.

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.

Author information

1
Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA; Section of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address: katerina.politi@yale.edu.
2
Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
3
Section of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address: thomas.lynch@yale.edu.

Abstract

The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired resistance to the current clinical EGFR tyrosine kinase inhibitors. In tyrosine kinase inhibitor-resistant lung tumors, rociletinib and AZD9291 are highly active when T790M is present and modestly active when T790M is absent.

PMID:
26058074
DOI:
10.1016/j.ccell.2015.05.012
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center